Caroline's Feed
Oct 18, 2012

Focus on new Actelion drug as Tracleer sales slip

ZURICH (Reuters) – Hopes for a key new heart and lung drug overshadowed nine-month results from Actelion Ltd, which showed a modest 4 percent slide in sales of the Swiss group’s current mainstay Tracleer.

Europe’s largest biotechnology company said on Thursday net income rose a higher-than-expected 16 percent, helped by cost cutting, prompting it to reiterate its 2012 outlook.

Oct 16, 2012

Roche sees more cancer success as sales top forecast

ZURICH (Reuters) – Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments helped it to top forecasts in the third quarter.

Most of Roche’s best-selling cancer drugs do not face imminent generic competition, sparing it the pain from a wave of patent expiries currently sweeping the global drugs industry.

Sep 20, 2012

Robust exports a ray of hope to limping Swiss economy

ZURICH, Sept 20 (Reuters) – Swiss exports grew robustly in
August, led by the key chemicals and pharmaceuticals sectors,
suggesting the economy is holding up well despite slowing global
growth as firms are managing to ride out the impact of a strong
franc.

Exports rose 4.4 percent year-on-year in August to 15.54
billion Swiss francs ($16.76 billion), accelerating from growth
of 0.8 percent in July, the Federal Customs Office said on
Thursday.

Sep 14, 2012

Swiss campaigner scents victory in fat cat pay battle

BERNE, Sept 14 (Reuters) – A Swiss
businessman-turned-politician is confident citizens will vote to
impose some of the tightest controls on fat cat pay in the
world, rejecting warnings from the country’s powerful business
lobby that the measures will scare big companies away.

Thomas Minder, elected last year as an independent member of
the upper house of parliament, has led a four-year campaign to
give shareholders a binding vote on the pay of company managers
and directors as well as ban golden handshakes and parachutes.

Jul 17, 2012

Feature : No free beer when frugal Swiss get their say

GLARUS, Switzerland (Reuters) – On a soggy Sunday in May, some 6,000 residents of the Swiss canton of Glarus gathered in a public square to have their say on whether to raise the local transport budget, ban attack dogs and reintroduce free burials.

Dating back to 1387, Glarus is one of only two remaining Swiss community assemblies or ‘Landsgemeinde’ – a forerunner of the country’s system of direct democracy, established in 1848, which gives citizens the final say on almost every single policy put forward at a local, cantonal or national level.

Jul 17, 2012

No free beer when frugal Swiss get their say

GLARUS, Switzerland (Reuters) – On a soggy Sunday in May, some 6,000 residents of the Swiss canton of Glarus gathered in a public square to have their say on whether to raise the local transport budget, ban attack dogs and reintroduce free burials.

Dating back to 1387, Glarus is one of only two remaining Swiss community assemblies or ‘Landsgemeinde’ – a forerunner of the country’s system of direct democracy, established in 1848, which gives citizens the final say on almost every single policy put forward at a local, cantonal or national level.

Jul 5, 2012

Barry Callebaut backs outlook amid Q3 slowdown

ZURICH, July 5 (Reuters) – Barry Callebaut, the
world’s largest chocolate products maker, said on Thursday it
was confident it would meet its financial targets despite a
slowdown in third-quarter volume growth.

Sales volumes slowed in the third quarter to 6.5 percent
from 6.7 percent in the first six months, sharply missing the
average analyst forecast of 10.7 percent in a Reuters poll.

Jul 5, 2012

Barry Callebaut confident on targets after Q3 rise

ZURICH, July 5 (Reuters) – Barry Callebaut, the
world’s largest chocolate products maker, said on Thursday it
was confident it would meet its financial targets despite a
slowdown in third-quarter volume growth.

Sales volumes slowed in the third quarter to 6.5 percent
from 6.7 percent in the first six months, sharply missing the
average analyst forecast of 10.7 percent in a Reuters poll.

Jul 3, 2012

Analysis: After Roche merger, biotech tail wags big pharma dog

ZURICH (Reuters) – When Roche paid $46.8 billion in 2009 to gain full ownership of Genentech, fears were rife that the arrival of the Swiss men in suits would stifle the free-wheeling innovative culture at the California-based biotech.

Three years on, however, the jeans-wearing scientists in San Francisco have proven they are the ones driving the drugs pipeline of the 116-year-old Basel-based pharma giant, casting a shadow over Roche’s own research operations.

Jul 1, 2012

Liechtenstein votes to keep prince’s veto

VADUZ (Reuters) – Voters in Liechtenstein rejected a proposal to abolish the ruling prince’s right to veto the results of popular referendums on Sunday, underscoring how citizens see the ruling family as integral to the principality’s wealth and stability.

The referendum was proposed by pro-democracy campaigners after Crown Prince Alois von und zu Liechtenstein said last year he would block the legalization of abortion if citizens approved it in a referendum. In the end, citizens rejected it anyway.